ALX Oncology Holdings Q2 EPS $(0.76) Beats $(0.77) Estimate
Portfolio Pulse from Benzinga Newsdesk
ALX Oncology Holdings (NASDAQ:ALXO) reported a Q2 EPS of $(0.76), beating the analyst consensus estimate of $(0.77) by 1.3%. This represents a 9.52% improvement over the $(0.84) per share loss from the same period last year.
August 08, 2024 | 9:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ALX Oncology Holdings reported a Q2 EPS of $(0.76), beating the analyst consensus estimate of $(0.77) by 1.3%. This is a 9.52% improvement over the $(0.84) per share loss from the same period last year.
The better-than-expected EPS and year-over-year improvement indicate positive financial performance, likely boosting investor confidence and short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100